Veritas In Silico (TYO:130A) and Dexerials (TYO:4980) said they will jointly develop a high-speed and highly accurate spectroscopic method for RNA structure analysis, according to a Tuesday filing on the Tokyo Stock Exchange.

The collaboration follows proof-of-concept studies begun in December 2023 and aims to establish a non-destructive, rapid measurement method within three years. Veritas will design RNA strands and conduct structural analysis, while Dexerials will apply its spectroscopic and data analysis technologies using machine learning.

Veritas said the new method is expected to enhance its ibVIS platform for mRNA-targeted drug discovery and could later be offered commercially for RNA quality control and manufacturing applications.